Inherited Disease
Seraseq® Inherited Cancer DNA Mix v2
Details
Resources
Specifications
The Seraseq Inherited Cancer DNA Mix v2 is a reference material intended for use in the development, validation, and evaluation of routine performance of Next Generation Sequencing (NGS) (and other amplified nucleic acid-based methods) that identify inherited (germline) variants in genes associated with hereditary cancer such as BRCA1, BRCA2, MHS2 and many others.
This high-quality reference material is a mixture of synthetic DNA constructs and genomic DNA extracted from the human cell line GM24385, formulated to simulate a heterozygous state for each mutation at a 50% variant allele frequency. It contains an unprecedented 61 synthetic mutations in 55 cancer-predisposing genes allowing laboratories to address assay challenges with a diverse array of mutations, including complex and hard-to-find variants such as the MSH2 Boland inversion, PMS2 pseudogene homologous variant, and EPCAM 3' large deletion (see technical spreadsheet for detailed information).
FEATURES AND BENEFITS
- Comprehensive Variant Coverage: Screen confidently for 61 clinically relevant variants across 56 cancer-associated genes. This enhanced coverage offers 2.5 times more mutations than our previous version, ensuring even rare and challenging variants are accounted for.
- Unmatched Complexity: incorporates difficult-to-detect mutations, such as the MSH2 Boland inversion, PMS2 pseudogene homologous variant, and EPCAM 3' large deletion, ensuring robust testing capabilities.
- High Variant Diversity: includes deletions, duplications, insertions, INDELs, SNVs, and inversions as well as a variety of complex variant types such as homopolymer variants, high-GC region variants, microsatellite variants, whole exon deletion, and deep splice site variants.
- Single-Vial Convenience: Simplify workflows with a highly multiplexed reference material packaged in a single vial, reducing costs and saving time while boosting QC consistency.
- Regulatory Compliance Support: designed to support compliance with regulatory standards like CAP, CLIA ensures your lab meets performance, quality, and reporting requirements effortlessly.
- Sustainable source: Manufactured in GMP-compliant, ISO 13485-certified facilities, the Seraseq Inherited Cancer DNA Mix v2 offers lot-to-lot consistency and an uninterrupted supply chain.
Package Insert for Seraseq Inherited Cancer DNA Mix v2
Safety Data Sheet for Seraseq Inherited Cancer DNA Mix v2
Technical Spreadsheet for Seraseq Inherited Cancer DNA Mix v2
Seraseq Inherited Cancer DNA Mix v2
Product Sheet for Seraseq Inherited Cancer DNA Mix v2
Product Specifications |
|
Number of genes |
61 |
Number of variants |
55 |
Variant allele Frequency % (VAF) |
50 |
Number of vial |
1 |
Fill Volume |
25 µL (actual fill volume: 30 µL) |
Concentration |
10 ng/µL |
Total Mass |
>250 ng |
Matrix |
Purified DNA in Buffer (Tris/EDTA) |